Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 157 от 222

Набира участници Фаза 1/2

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

Multiple Myeloma

CO43923 is a platform study that will evaluate the safety, efficacy, and pharmacokinetics (PK) of multiple treatment combinations, as monotherapy or in combination, in participants with multiple myeloma (MM). The study is designed with the flexibility to open new treatment substudies as new treatments become available. Information regarding the opened substudies are found below.

Начало: 14.11.2023 Край: 31.07.2028 Възраст: от 18 г. Лечение

Australia, France, Germany +3 Hoffmann-La Roche NCT05583617

Набира участници Фаза 1/2

A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Solid Tumor

This is a phase 1/2 multicenter, open-label, first-in-human study of IBI130. It includes a phase 1 dose escalation and expansion section to identify MTD/RP2D of IBI130, plan to enroll 20\~182 subjects,and a phase 2 to explore efficacy, safety and tolerability of IBI130 at RP2D in specified types of solid tumor.Approximately 150 evaluable subjects will be enrolled for phase 2.

Начало: 14.11.2023 Край: 31.10.2026 Възраст: от 18 г. Лечение

Australia Innovent Biologics (Suzhou) Co. Ltd. NCT05923008

Набира участници Фаза 3

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

Cytomegalovirus (CMV)

The main aim of this study is to find out the safety, tolerability and pharmacokinetics (PK) of maribavir for the treatment of CMV infection in children and teenagers after HSCT or SOT and to identify the optimal dose of maribavir using a 200 milligrams (mg) tablet formulation or powder for oral suspension. The participants will be treated with maribavir for 8 weeks. Participants need to visit their doctor during 12-week follow-up period.

Начало: 13.11.2023 Край: 18.01.2027 Възраст: до 17 г. Лечение

Australia, Belgium, Brazil +8 Takeda NCT05319353

Набира участници Фаза 3

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Non-small Cell Lung Cancer (NSCLC)

The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR mutations (hereafter referred to as EGFR mutations or EGFR-mutated) or any of the follow genomic alterations: ALK gene rearrangements, ROS1 rearrangements, BRAF V600E mutations, NTRK gene fusions, MET exon 14 skipping mutations, RET rearrangements, or less common EGFR point mutations of exon 20 S768I, exon 21 L861Q, or exon 18 G719X mutations. The primary hypotheses are that sacituzumab tirumotecan is: (1) superior to chemotherapy with respect to progression-free survival (PFS) per RECIST 1.1 as assessed by BICR in NSCLC with EGFR mutations; and (2) superior to chemotherapy with respect to overall survival (OS) in NSCLC with EGFR mutations.

Начало: 12.11.2023 Край: 11.03.2030 Възраст: от 18 г. Лечение

Australia, Brazil, Canada +22 Merck Sharp & Dohme LLC NCT06074588

Набира участници

A Study of Glycemic Control in Left Ventricular Assist

Type 2 Diabetes Mellitus Hyperglycemia Hypoglycemia

The study is being conducted to understand if the hemoglobin A1c, a measurement of control of blood sugars over a 3-month time, is valid in patients with Left Ventricular Assist Devices (LVADs) in place. To understand whether it is an adequate measurement, the investigators will compare the A1c to results from a continuous glucose monitor (CGM) measurement of blood sugars. By monitoring blood sugars continuously, the investigators will also assess whether they can get better control of blood sugars with a CGM, including avoiding low blood sugars.

Начало: 10.11.2023 Край: 01.07.2026 Възраст: от 18 г.

United States Mayo Clinic NCT05933161

Набира участници

Spermatogonial Stem Cell (SSC) Transplant and Testicular Tissue Grafting

Infertility, Male Cancer Autoimmune Disorder

Spermatogonial stem cell transplantation through ultrasound guided rete testis injection and testicular tissue grafting will be performed for participants who have frozen testicular tissue prior to gonadotoxic therapy. The purpose of this study is to test the safety and feasibility of these transplant technologies and restore fertility for these participants.

Начало: 10.11.2023 Край: 31.05.2030

United States University of Pittsburgh NCT04452305

Набира участници Фаза 3

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Unresectable Pleural Mesothelioma

This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.

Начало: 09.11.2023 Край: 16.11.2028 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +17 AstraZeneca NCT06097728

Набира участници

Hyperbaric Oxygen Therapy for Persistent Post Stroke Depression

Post Stroke Depression

The study evaluates the effect of HBOT on depression in patients suffering from persistent symptoms of post stroke depression (PSD) in an double blind sham control study.

Начало: 08.11.2023 Край: 01.12.2030 Възраст: 50–85 г.

Israel Assaf-Harofeh Medical Center NCT07423273

Набира участници Фаза 1

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

Metastatic Colorectal Carcinoma Metastatic Malignant Solid Neoplasm Stage IV Colorectal Cancer AJCC v8 Unresectable Colorectal Carcinoma +1

This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with the usual treatment with capecitabine in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable) and that it has progressed on previous standard treatment. ZEN003694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that over produce BET protein. Capecitabine is in a class of medications called antimetabolites. It is taken up by cancer cells and breaks down into fluorouracil, a substance that kills cancer cells. Giving ZEN003694 in combination with capecitabine may be safe in treating patients with metastatic or unresectable solid tumors.

Начало: 08.11.2023 Край: 30.06.2026 Възраст: от 18 г.

United States National Cancer Institute (NCI) NCT05803382

Набира участници Фаза 1

AMT-253 in Patients With Selected Advanced Solid Tumours

Advanced Solid Tumor

This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-253, in Patients with Advanced Solid Tumors

Начало: 06.11.2023 Край: 30.12.2026 Възраст: от 18 г. Лечение

Australia Multitude Therapeutics (Australia) Pty Ltd NCT05906862

Набира участници Фаза 1/2

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

Lymphoblastic Leukemia

The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia cells outer membrane.

Начало: 03.11.2023 Край: 01.12.2033 Възраст: до 1 г.

Canada, United States Tanja Andrea Gruber NCT05848687

Набира участници

Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI

Carcinoma, Hepatocellular Cirrhosis

The study is a randomized trial of two different screening methods for early detection of liver cancer in patients with cirrhosis of the liver. The goal of PREMIUM is to compare an abbreviated version of the diagnostic gold standard for HCC (aMRI) +AFP to the standard-of-care screening (US+AFP) in patients at high risk of developing HCC. The investigators hypothesize that HCC will be detected at earlier stages, allowing for more curative treatments and resulting in a reduction in HCC-related mortality.

Начало: 03.11.2023 Край: 01.09.2031 Възраст: 18–75 г.

United States VA Office of Research and Development NCT05486572

Набира участници

ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions

Breast Cancer

This prospective, blinded, single-arm study aims to test the performance of nanomechanical phenotype in predicting tumor type, tumor aggressiveness, and neoadjuvant treatment response compared to the gold standard of histopathological assessment. The study involves patients with suspicious breast lesions who will undergo a breast biopsy procedure indicated by standard of care. The nanomechanical phenotype will be measured on the freshly obtained breast biopsies or tissue from breast surgeries.

Начало: 02.11.2023 Край: 01.11.2035 Възраст: от 18 г.

Spain, Switzerland, United States ARTIDIS AG NCT06085833

Набира участници

Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria

Urothelial Carcinoma

It is currently debated whether the use of invasive standard of care procedures, such as cystoscopy, a procedure which involves inserting a thin camera, called a cystoscope, into the bladder to look for signs of disease, is appropriate for patients with microscopic hematuria (blood in the urine that cannot be seen with the naked eye). This is because the risk of disease (bladder cancer - urothelial carcinoma) is relatively low in this population group, approximately 3%. Invasive procedures such as cystoscopy can cause anxiety and pain, in addition to other potential side effects. This has resulted in low admittance for cystoscopy among patients with hematuria (blood in urine) in urology clinics. Therefore, there is a need for a simpler, non-invasive test that can accurately detect the presence or absence of disease (urothelial carcinoma) in patients with microscopic hematuria. Cxbladder, a non-invasive, urine-based test, has the potential to fill this role.

Начало: 02.11.2023 Край: 30.06.2026 Възраст: 18–89 г.

United States Pacific Edge Limited NCT05889195

Набира участници

IMPlementation of Evidence Based Facility and Community Interventions to Reduce the Treatment Gap for depRESSion

Depression

The goal of this Hybrid Type 2 Implementation-Effectiveness Cluster Randomised Controlled Trial is to reduce the treatment gap for depression through the integrated implementation of interventions in facility and community platforms, in Goa, India. The primary question is to examine whether a community intervention ("Community Model") enhances the demand for, and improves the outcomes of, an evidence-based, brief psychological treatment for depression delivered by non-specialist health workers in primary health care facilities ("Facility Model"). Participants in the Facility Model arm will receive only a psychosocial intervention for depression (the Healthy Activity Program - HAP) while participants in the Community Model will receive both the HAP and the community intervention. We will compare the Facility Model and the Community Model to assess if the latter is superior in increasing the demand for depression treatment in primary care, increasing uptake of treatment by people with depression, increasing treatment completion rates, and reducing the severity of depression.

Начало: 01.11.2023 Край: 30.04.2026 Възраст: от 18 г.

India Sangath NCT05890222

Набира участници

Trifecta-Lung cfDNA-MMDx Study

Lung Transplantation

Demonstrate the relationship between dd-cfDNA levels and HLA antibodies in blood transplant recipient and Demonstrate the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from lung transplants.

Начало: 01.11.2023 Край: 01.12.2027 Възраст: от 18 г.

Australia, Canada, Czechia +1 University of Alberta NCT05837663

Набира участници Фаза 1

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

Relapsed/Refractory Multiple Myeloma

This study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of ISB 2001 in participants with relapsed/refractory multiple myeloma (R/R MM).

Начало: 01.11.2023 Край: 01.07.2027 Възраст: от 18 г. Лечение

Australia, France, India +4 Ichnos Sciences SA NCT05862012

Набира участници

A Study to Investigate the Feasibility and Respiratory Effects of Stimulating Two Functional Targets (neural And/or Muscular) for the Treatment of Obstructive Sleep Apnea

Sleep Apnea Sleep Apnea, Obstructive Sleep Apnea Syndromes Sleep Disorder

This proof-of-concept study is to collect acute and short-term sub-acute (if applicable) changes in respiratory parameters following the percutaneous placement of electrode arrays. Acute placement and data collection will be conducted while performing a Drug Induced Sleep Endoscopy (DISE) where the goal will be to quantify changes in airflow with stimulation. Data will also be collected during a one- or two-night polysomnography (PSG) to investigate airflow and sleep stability responses with and without different levels of stimulation during sleep. Where feasible, OSA severity data will be collected, as measured via the apnea/hypopnea index (AHI) with stimulation versus without stimulation as a secondary objective. Both data collections will be done when stimulating the hypoglossal nerve (HGN) or Genioglossus muscle (GG) and a second functional target (Ansa Cervicalis - AC) or the strap muscles (sternohyoid and sternothyroid) with a set of electrode arrays either in combination or separately.

Начало: 01.11.2023 Край: 01.11.2024 Възраст: от 18 г. Фундаментална наука

Australia Invicta Medical Inc. NCT06627127

Набира участници Фаза 3

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Metastatic Breast Cancer

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.

Начало: 31.10.2023 Край: 01.04.2028 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +14 LeonaBio NCT05696626

Набира участници Фаза 1

Universal CAR-T Cells Targeting Multiple Myeloma

Multiple Myeloma in Remission

The aim of this study is to assess the feasibility, safety and efficacy of universal CAR T cells targeting multiple myeloma. Another goal of the study is to learn more about the persistence and function of the universal CAR T cells in the body.

Начало: 31.10.2023 Край: 31.12.2026 Възраст: 18–80 г.

China Shenzhen Geno-Immune Medical Institute NCT06006741

1 … 155 156 157 158 159 … 222